A Multicenter, Open-label Study of Rhopressa (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Netarsudil (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Acronyms MOST
- Sponsors Aerie Pharmaceuticals
Most Recent Events
- 14 Nov 2019 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Topline results presented in an Aerie Pharmaceuticals presentation. (https://investors.aeriepharma.com/static-files/98492e81-5eb6-49f6-bf35-8b20a13a644b)
- 06 Nov 2019 According to an Aerie Pharmaceuticals media release, study results will be presented on Aerie's third-quarter conference call.